

CURRICULUM VITAE



Date and place of birth: 9.6.1987, Šternberk, Czech Republic
Permanent residence: Nemocniční 1191, 78391 Uničov, CZ
Temporary residence: Budilova 5, 180 00 Prague 8, CZ
Phone: (+420) 732155195
E-mail: vockovap@gmail.com / petra.vockova@lf1.cuni.cz

Education:

- 2006-2012 1st Medical Faculty of Charles University in Prague
Study Programme: General Medicine
- 2012 - now Postgradual student, Institute of Pathological Physiology, 1st Medical Faculty of Charles University in Prague
Study Programme: Human Physiology and Pathophysiology
Mentor: Ass. Prof. Pavel Klener, PhD, MD
Topic: The Role of Antiangiogenic Therapy in Mantle Cell Lymphoma
- 23.11.2017 Approbation exam in the field of Haematology and Transfusion Medicine

Work Experience:

- 2012 - 2017 Resident Physician, Department of Haematology, General Teaching Hospital in Prague
- 2013 - now Assistant Professor, Institute of Pathological Physiology, 1st Medical Faculty of Charles University in Prague
- 2017 - now Haematologist, Department of Haematology, General Teaching Hospital in Prague

Educational skills:

- 2012 - now Education of "Pathological physiology" – 3rd year medical students, Institute of Pathological Physiology, 1st Medical Faculty of Charles University in Prague
- 2012 - now Education of Internal Medicine - 3rd-6th year medical students, Department of Haematology, General Teaching Hospital in Prague and 1st Medical Faculty of Charles University in Prague
- 2012 - now Education of "Pathological physiology" – 3rd year dental students, Institute of Pathological Physiology, 1st Medical Faculty of Charles University in Prague

Grant Projects:

- 2017-2018 GAUK (main investigator) - Topic: Combined immunotherapy of aggressive non-Hodgkin lymphomas using anti-CD38 antibody daratumumab, ex vivo cultured NK cells and immunomodulatory agent lenalidomide

Membership in Professional Associations:

- 2012 - now Czech Medical Chamber
- 2014 - now Czech Medical Association of J. E. Purkyně

Publications:

[1] Klanova M, Soukup T, Jaksá R, Molinsky J, Lateckova L, Maswabi BCL, Prukova D, Brezinova J, Michalova K, **Vockova P**, Hernandez-Ilizaliturri F, Kulvait V, Zivny J, Vokurka M, Necas E, Trneny M, Klener P. Mouse models of mantle cell lymphoma: complex changes in gene expression and phenotype of engrafted MCL cells: implications for preclinical research. Lab Invest. 2014 Jul;94(7):806-17. doi: 10.1038/labinvest.2014.61. Epub 2014 May 26. (IF = 3,4)

[2] Klanova M, Lorkova L, Vit O, Maswabi B, Molinsky J, Pospisilova J, **Vockova P**, Mavis C, Lateckova L, Kulvait V, Vejmelkova D, Jaksá R, Hernandez F, Trneny M, Vokurka M, Petrak J, Klener P Jr.

Downregulation of deoxycytidine kinase in cytarabine-resistant mantle cell lymphoma cells confers cross-resistance to nucleoside analogs gemcitabine, fludarabine and cladribine, but not to other classes of anti-lymphoma agents. *Mol Cancer*. 2014 Jun 27. (IF = 4,2)

[3] Otáhal P, Průková D, Král V, Fabry M, **Vočková P**, Latečková L, Trněný M, Klener P. Lenalidomide enhances antitumor functions of chimeric antigen receptor modified T cells. *Oncoimmunology*. 2015 Dec 3. (IF = 3,5)

[4] Vocka M, Langer D, Petrtyl J, **Vockova P**, Hanus T, Kalousova M, Zima T, Petruzalka L. Trefoil factor family (TFF) proteins as potential serum biomarkers in patients with metastatic colorectal cancer. *Neoplasma*. 2015 Apr 13. (IF = 2,0)

[5] Lorkova L, Scigelova M, Arrey TN, Vit O, Pospisilova J, Doktorova E, Klanova M, Alam M, **Vockova P**, Maswabi B, Klener P Jr, Petrak J. Detailed Functional and Proteomic Characterization of Fludarabine Resistance in Mantle Cell Lymphoma Cells. *PLoS One*. 2015 Aug 18. (IF = 4,4)

[6] Klanova M, Andera L, Soukup J, Svadlenka J, Benesova S, Brazina J, Prukova D, Vejmelkova D, Jaksá R, Helman K, **Vockova P**, Lateckova L, Molinsky J, Maswabi B, Alam M, Kodet R, Pytlík R, Trneny M, Klener P Jr. Targeting of BCL2 family proteins with ABT-199 and homoharringtonine reveals BCL2- and MCL1-dependent subgroups of diffuse large B-cell lymphoma. *Clin Cancer Res*. 2015 Oct 14. (IF = 9,6)

[7] Czuczman NM, Barth MJ, Gu J, Neppalli V, Mavis C, Frys SE, Hu Q, Liu S, Klener P, **Vockova P**, Czuczman MS, Hernandez-Ilizaliturri FJ. Pevonedistat, a NEDD8-activating enzyme inhibitor, is active in mantle cell lymphoma and enhances rituximab activity in vivo. *Blood*. 2016 Mar 3;127(9):1128-37. doi: 10.1182/blood-2015-04-640920. Epub 2015 Dec 16. (IF = 13,2)

[8] Molinsky J, Maswabi B, Prukova D, Klanova M, **Vockova P**, Zikmund T, Savvulidi F, Alam M, Sefc L, Vokurka M, Obrtlíkova P, Trneny M, Klener P Jr. Significantly higher numbers of proB cells in healthy Caucasians compared to Asians: Is there association with incidence of CLL? *Blood Cells Mol Dis*. 2016 Mar;57:118-9. doi: 10.1016/j.bcmd.2015.12.001. Epub 2015 Dec 2. (IF = 1,9)

[9] Klanova M, Soukup T, Molinsky J, Lateckova L, **Vockova P**, Alam M, Zivny J, Trneny M, Klener P. Single-agent cytarabine is insufficient for the treatment of human mantle cell lymphoma in mouse xenograft model. *Neoplasma*. 2016 Jul 29;63(5). doi: 10.4149/neo_2016_515. (IF = 1,9)

[10] Maswabi BC, Molinsky J, Savvulidi F, Zikmund T, Prukova D, Tuskova D, Klanova M, **Vockova P**, Lateckova L, Sefc L, Zivny J, Trneny M, Klener P. Hematopoiesis in patients with mature B-cell malignancies is deregulated even in patients with undetectable bone marrow involvement. *Haematologica*. 2017 Apr;102(4):e152-e155. doi: 10.3324/haematol.2016.151571. Epub 2017 Jan 5. (IF = 9,1)

[11] Erdmann T, Klener P, Lynch JT, Grau M, **Vočková P**, Molinsky J, Tuskova D, Hudson K, Polanska UM, Grondine M, Mayo M, Dai B, Pfeifer M, Erdmann K, Schwammbach D, Zapukhlyak M, Staiger AM, Ott G, Berdel WE, Davies BR, Cruzalegui F, Trneny M, Lenz P, Barry ST, Lenz G. Sensitivity to PI3K and AKT inhibitors is mediated by divergent molecular mechanisms in subtypes of DLBCL. *Blood*. 2017 Feb 15. pii: blood-2016-12-758599. doi: 10.1182/blood-2016-12-758599. (IF = 15,1)

[12] Prukova D, Andera L, Nahacka Z, Karolova J, Svaton M, Klanova M, Havranek O, Soukup J, Svobodova K, Zemanova Z, Tuskova D, Pokorna E, Helman K, Forsterova K, Pacheco-Blanco M, **Vockova P**, Berkova A, Fronkova E, Trneny M, Klener P. Cotargeting of BCL2 with Venetoclax and MCL1 with S63845 Is Synthetically Lethal In Vivo in Relapsed Mantle Cell Lymphoma. *Clin Cancer Res*. 2019 Apr 19. doi: 10.1158/1078-0432.CCR-18-3275. (IF = 10,2)

Sum of times cited (21.6.2019): 107

H-index: 7